NYSE:USNA - USANA Health Sciences Stock Price, Price Target & More

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences declared that its board has initiated a stock buyback plan on Wednesday, July 26th 2017, which allows the company to buyback $64,600,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 46% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board believes its shares are undervalued.

USANA Health Sciences, Inc. (NYSE:USNA) issued its quarterly earnings data on Tuesday, April, 24th. The company reported $1.19 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.05 by $0.14. The firm had revenue of $292 million for the quarter, compared to analyst estimates of $268.93 million. USANA Health Sciences had a net margin of 6.47% and a return on equity of 27.92%. The firm's revenue was up 14.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.91 EPS. View USANA Health Sciences' Earnings History.

USANA Health Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for USANA Health Sciences.

USANA Health Sciences updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $4.25-4.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.37. The company issued revenue guidance of $1.13-1.17 billion, compared to the consensus revenue estimate of $1.12 billion.

2 brokerages have issued 12 month price objectives for USANA Health Sciences' shares. Their forecasts range from $95.00 to $95.00. On average, they anticipate USANA Health Sciences' stock price to reach $95.00 in the next year. This suggests that the stock has a possible downside of 12.7%. View Analyst Ratings for USANA Health Sciences.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to USANA Health Sciences include Stada Arzneimittel (STDAF), Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), Cyanotech (CYAN), GLG Life Tech (GLGLF), ImmuDyne (IMMD), FitLife Brands (FTLF), Nutra Pharma (NPHC), Tauriga Sciences (TAUG) and True Drinks Holdings, Inc Common Stock (TRUU).

Media coverage about USNA stock has been trending somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. USANA Health Sciences earned a news impact score of 0.14 on Accern's scale. They also assigned news headlines about the company an impact score of 46.68 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

USANA Health Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include WENTZ MYRON W (43.80%), Bank of Montreal Can (0.02%) and Campbell & CO Investment Adviser LLC (0.01%). Company insiders that own USANA Health Sciences stock include Daniel A Macuga, David Mulham Mulham, Deborah Woo, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Kevin Guest, Myron W Wentz, Paul A Jones, Robert Auciaux and Walter Noot. View Institutional Ownership Trends for USANA Health Sciences.

USNA stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for USANA Health Sciences.

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of USNA stock can currently be purchased for approximately $108.80.

USANA Health Sciences has a market capitalization of $2.63 billion and generates $1.05 billion in revenue each year. The company earns $62.53 million in net income (profit) each year or $4.06 on an earnings per share basis. USANA Health Sciences employs 1,810 workers across the globe.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]